OCS OCULIS HOLDING AG

Oculis Updates Share Capital

Oculis Updates Share Capital

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warrant exercises pursuant to the Company‘s Articles of Association, during the period from January 1, 2024, to December 31, 2024. 

As a result, the total number of registered shares as set forth in the Company’s Articles of Association has increased to 54,533,674. This increase has been registered with the Zug Commercial Register.

For more information, please visit:



Oculis Contact:

Ms. Sylvia Cheung, CFO

  

Investor & Media Relations:

LifeSci Advisors

Corey Davis, Ph.D.

  



EN
25/04/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Up...

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The prese...

14h / 34m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upc...

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presen...

14h / 34m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Updates Share Capital

Oculis Updates Share Capital ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warrant exercises pursuant to the Company‘s Articles of Asso...

April 25, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announces, in collaboration with EURETINA, the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute to Professor Tadayoni, the Company’s Chief Scientific Officer and a world-ren...

April 17, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipelin...

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2025 from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. To attend the event or participate virtually, please register . The event will pro...

April 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch